Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RAUVAL vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension (mild to moderate),Off-label: management of agitated states or psychiatric conditions (historically)
Hypertension
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Metabolized in the liver via CYP450 enzymes, primarily CYP3A4, to active and inactive metabolites.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
85-90% bound to albumin and alpha-1-acid glycoprotein.
~90%, primarily to albumin
0.6-1.0 L/kg; indicates extensive extravascular distribution.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Oral: 60-70% due to first-pass metabolism.
Oral: 50–60% (extensive first-pass metabolism)
No dose adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, dose reduction by 50% is recommended.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; maximum 1.5 mg daily.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Safety and efficacy not established in pediatric patients under 18 years.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at 1 mg orally once daily; consider slower titration due to increased sensitivity to orthostatic hypotension.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
May cause mental depression, especially at high doses, and should be discontinued if signs of depression appear.,Use with caution in patients with a history of peptic ulcer disease as it increases gastric acid secretion.,May cause orthostatic hypotension, tachycardia, and electrolyte disturbances.,Abrupt discontinuation may lead to withdrawal symptoms such as agitation, anxiety, and hypertension.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to rauwolfia serpentina or any component,Active peptic ulcer disease,Ulcerative colitis,History of mental depression, especially with suicidal tendencies,Electroconvulsive therapy (ECT) within 7 days
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as rauwolfia may potentiate pressor effects. Limit salt intake to support blood pressure control. Grapefruit juice may increase drug levels; avoid concurrent consumption.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairment.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Rauval is excreted in human milk; potential for serious adverse reactions in nursing infants. M/P ratio unknown. Breastfeeding is contraindicated.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No established dose adjustments; use is contraindicated in pregnancy due to known teratogenicity and fetotoxicity.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Rauval (rauwolfia alkaloids) is an antihypertensive that depletes catecholamines. Avoid in patients with history of depression or peptic ulcer disease. Onset is slow (weeks), so not for hypertensive emergencies. Monitor for orthostatic hypotension, especially at initiation. May cause nasal congestion and bradycardia. Discontinue at least 2 weeks before elective surgery to avoid anesthetic interactions.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not stop abruptly as it may cause rapid blood pressure increase.,Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.,Rise slowly from sitting or lying down to prevent falls due to low blood pressure.,Report any signs of depression, slow heartbeat, or unusual bruising/bleeding to your doctor.,Avoid alcohol, as it may worsen dizziness and drowsiness.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RAUVAL vs ALDORIL 15, answered by our medical review team.
RAUVAL is a Antihypertensive that works by Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RAUVAL and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RAUVAL is: 1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RAUVAL and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RAUVAL is classified as Category C. First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairme. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.